Carcinoma, Intraductal, Noninfiltrating
Papilloma, Intraductal
Carcinoma
Adenocarcinoma, Mucinous
Carcinoma, Pancreatic Ductal
Carcinoma, Papillary
Adenocarcinoma, Papillary
Carcinoma, Squamous Cell
Carcinoma, Hepatocellular
Carcinoma in Situ
Pancreatic Neoplasms
Cystadenoma, Mucinous
Neoplasms, Cystic, Mucinous, and Serous
Pancreatic Ducts
Carcinoma, Ductal, Breast
Carcinoma, Ductal
Pancreatic Cyst
Immunohistochemistry
Cystadenoma, Serous
Tumor Markers, Biological
Carcinoma, Basal Cell
Cholangiopancreatography, Magnetic Resonance
Cystadenocarcinoma, Mucinous
Cholangiopancreatography, Endoscopic Retrograde
Endosonography
Bile Ducts, Intrahepatic
Carcinoma, Lobular
Carcinoma, Transitional Cell
Prognosis
Pancreaticoduodenectomy
Neoplasm Staging
Neoplasms, Multiple Primary
Bile Ducts, Extrahepatic
Mucins
Breast
Pancreatic Juice
Carcinoma, Bronchogenic
Carcinoma, Adenoid Cystic
Precancerous Conditions
Gene Expression Regulation, Neoplastic
Carcinoma, Small Cell
Carcinoma, Medullary
Cystadenocarcinoma
Retrospective Studies
Mucin-2
Cystadenoma
Lymphatic Metastasis
Pancreatitis
Pancreas
Carcinoma, Neuroendocrine
Glycodeoxycholic Acid
Common Bile Duct Neoplasms
Neoplasm Recurrence, Local
Tomography, X-Ray Computed
Tumor Cells, Cultured
Salivary Ducts
Biopsy
Carcinoma, Mucoepidermoid
Treatment Outcome
Neoplasm Proteins
Carcinoma, Endometrioid
Neoplasm Metastasis
Head and Neck Neoplasms
Survival Rate
Hyperplasia
Carcinoma, Embryonal
Exudates and Transudates
Ampulla of Vater
Carcinoma, Merkel Cell
Lithiasis
Immunoenzyme Techniques
Medical Device Recalls
Disease Progression
Ovarian Neoplasms
Adrenocortical Carcinoma
Carcinoma, Verrucous
Carcinoma, Signet Ring Cell
Mastectomy, Segmental
Common Bile Duct
RNA, Messenger
Loss of Heterozygosity
Neoplasm Grading
Tumor Suppressor Protein p53
Survival Analysis
Carcinoma, Acinar Cell
Mixed Tumor, Malignant
Reverse Transcriptase Polymerase Chain Reaction
Pancreatitis, Chronic
Mice, Nude
Smad4 Protein
Carcinoma, Large Cell
Papilloma
Hepatic Duct, Common
Prostatic Intraepithelial Neoplasia
Endoscopy
Fibroadenoma
Mammary Neoplasms, Experimental
Fatal Outcome
Follow-Up Studies
Laryngeal Neoplasms
Pancreatitis, Acute Necrotizing
Sensitivity and Specificity
Mutation
Combined Modality Therapy
Mucin-1
Digestive System Fistula
Neoplasm Transplantation
Adenocarcinoma, Follicular
Ultrasonography, Mammary
Tomography Scanners, X-Ray Computed
Jaundice, Obstructive
Mammary Glands, Human
Disease-Free Survival
Biopsy, Fine-Needle
Cell Transformation, Neoplastic
Cytodiagnosis
Antigens, Neoplasm
Genes, Tumor Suppressor
Predictive Value of Tests
Magnetic Resonance Imaging
Embryonal Carcinoma Stem Cells
Fibrocystic Breast Disease
Bile Ducts
Cholangiography
Carcinoma, Papillary, Follicular
Endoscopes, Gastrointestinal
Carcinoma, Non-Small-Cell Lung
Kaplan-Meier Estimate
CA-19-9 Antigen
Endometrial Neoplasms
Adenocarcinoma, Clear Cell
Colorectal Neoplasms
Cyclin-Dependent Kinase Inhibitor p16
Cholestasis, Extrahepatic
alpha-Fetoproteins
Apoptosis
Pseudomyxoma Peritonei
Dilatation, Pathologic
Cystadenocarcinoma, Serous
Base Sequence
Carcinoma, Lewis Lung
Calculi
Tumor Suppressor Proteins
Biopsy, Needle
Cell Division
Microsatellite Repeats
Tissue Array Analysis
Cholestasis
Keratins
Cisplatin
Proto-Oncogene Proteins
Lymph Nodes
DNA-Binding Proteins
Paraffin Embedding
Risk Factors
High frequency of germ-line BRCA2 mutations among Hungarian male breast cancer patients without family history. (1/1031)
To determine the contribution of BRCA1 and BRCA2 mutations to the pathogenesis of male breast cancer in Hungary, the country with the highest male breast cancer mortality rates in continental Europe, a series of 18 male breast cancer patients and three patients with gynecomastia was analyzed for germ-line mutations in both BRCA1 and BRCA2. Although no germ-line BRCA1 mutation was observed, 6 of the 18 male breast cancer cases (33%) carried truncating mutations in the BRCA2 gene. Unexpectedly, none of them reported a family history for breast/ovarian cancer. Four of six truncating mutations were novel, and two mutations were recurrent. Four patients (22%) had a family history of breast/ovarian cancer in at least one first- or second-degree relative; however, no BRCA2 mutation was identified among them. No mutation was identified in either of the genes in the gynecomastias. These results provide evidence for a strong genetic component of male breast cancer in Hungary. (+info)VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. (2/1031)
Recently, monoclonal antibodies against the human vascular endothelial growth factor receptor VEGFR-3 were shown to provide a specific antigenic marker for lymphatic endothelium in various normal tissues. In this study we have investigated the expression of VEGFR-3 and its ligand VEGF-C in normal breast tissue and in breast tumors by immunohistochemistry. VEGFR-3 was weakly expressed in capillaries of normal breast tissue and in fibroadenomas. In intraductal breast carcinomas, VEGFR-3 was prominent in the "necklace" vessels adjacent to the basal lamina of the tumor-filled ducts. VEGF receptor 1 and 2 as well as blood vessel endothelial and basal lamina markers were colocalized with VEGFR-3 in many of these vessels. Antibodies against smooth muscle alpha-actin gave a weak staining of the necklace vessels, suggesting that they were incompletely covered by pericytes/smooth muscle cells. A highly elevated number of VEGFR-3 positive vessels was found in invasive breast cancer in comparison with histologically normal breast tissue (P < 0.0001, the Mann-Whitney test). VEGF-C was located in the cytoplasm of intraductal and invasive cancer cells. The results demonstrate that the expression of VEGFR-3 becomes up-regulated in the endothelium of angiogenic blood vessels in breast cancer. The results also suggest that VEGF-C secreted by the intraductal carcinoma cells acts predominantly as an angiogenic growth factor for blood vessels, although this paracrine signaling network between the cancer cells and the endothelium may also be involved in modifying the permeabilities of both blood and lymphatic vessels and metastasis formation. (+info)Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. (3/1031)
The generation of vascular stroma is essential for solid tumor growth and involves stimulatory and inhibiting factors as well as stromal components that regulate functions such as cellular adhesion, migration, and gene expression. In an effort to obtain a more integrated understanding of vascular stroma formation in breast carcinoma, we examined expression of the angiogenic factor vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF); the VPF/VEGF receptors flt-1 and KDR; thrombospondin-1, which has been reported to inhibit angiogenesis; and the stromal components collagen type I, total fibronectin, ED-A+ fibronectin, versican, and decorin by mRNA in situ hybridization on frozen sections of 113 blocks of breast tissue from 68 patients including 28 sections of breast tissue without malignancy, 18 with in situ carcinomas, 56 with invasive carcinomas, and 8 with metastatic carcinomas. A characteristic expression profile emerged that was remarkably similar in invasive carcinoma, carcinoma in situ, and metastatic carcinoma, with the following characteristics: strong tumor cell expression of VPF/VEGF; strong endothelial cell expression of VPF/VEGF receptors; strong expression of thrombospondin-1 by stromal cells and occasionally by tumor cells; and strong stromal cell expression of collagen type I, total fibronectin, ED-A+ fibronectin, versican, and decorin. The formation of vascular stroma preceded invasion, raising the possibility that tumor cells invade not into normal breast stroma but rather into a richly vascular stroma that they have induced. Similarly, tumor cells at sites of metastasis appear to induce the vascular stroma in which they grow. We conclude that a distinct pattern of mRNA expression characterizes the generation of vascular stroma in breast cancer and that the formation of vascular stroma may play a role not only in growth of the primary tumor but also in invasion and metastasis. (+info)An audit of breast cancer pathology reporting in Australia in 1995. (4/1031)
To measure the quality of pathology reporting of breast cancer and establish a baseline against which future changes can be measured, we audited item completeness in breast cancer reports in Australia in 1995 before the release of specific recommendations from the Australian Cancer Network. Tumour type and size were given in reports of invasive breast cancer for 93% of women, 70% had, in addition, grade and clearance of the margins while only 28% had all recommended information. The most complete items in reports were histological type of breast cancer (99.6% of cases), tumour size (94%, 95% confidence interval (CI) 92-95) and margins of excision (87%, 95% CI 85-89). Histological grade (84%, 95% CI 82-86 of cases) and presence or absence of ductal carcinoma in situ (DCIS) (79%, 95% CI 77-81) were less complete and vessel invasion (61%, 95% CI 58-63) and changes in non-neoplastic breast tissue adjacent to the breast cancer (68%, 95% CI 66-71) the least complete. Less than half the reports of DCIS reported on tumour size (49%, 95% CI 42-57), presence or absence of necrosis (41%, 95% CI 34-49) or nuclear grade (39%, 95% CI 31-46). Around 1500 reports were identified as issued by 147 laboratories and 392 pathologists; 69% of pathologists issued fewer than two reports a month in the audit. We concluded that infrequency of reporting may have contributed to incompleteness of reporting. In addition, we found significant variation across Australian states with some indication that reporting was consistently poor in one state. The audit highlighted areas for improvement for breast cancer reporting in Australia. Research evidence suggests that multifaceted strategies are needed to assist practitioners with implementing more uniform reporting standards. (+info)Urokinase plasminogen activator receptor (CD87) expression of tumor-associated macrophages in ductal carcinoma in situ, breast cancer, and resident macrophages of normal breast tissue. (5/1031)
Macrophages concentrate urokinase-type plasminogen activator (uPA) at the cell surface by expressing urokinase receptors (uPAR) in order to focus the pericellular space plasminogen-dependent proteolysis important in matrix remodeling and cell movement. This study examines the uPAR levels of tumor-associated macrophages (TAM) of invasive breast carcinomas, of TAMs from ductal carcinoma in situ (DCIS) and of macrophages derived from normal (non-tumor) breast tissue. TAMs from invasive breast carcinomas (n = 30), from DCIS (n = 12), and macrophages from normal breast tissue (n = 30) were cultured and immunocytochemically phenotyped by using a panel of antibodies. Urokinase receptor levels were determined by Western blot analysis and in cell-free supernatants by enzyme-linked immunosorbent assay. Urokinase receptor cell surface fluorescence intensity was determined by FACS and by confocal laser scan microscopy. Urokinase-receptor mRNA was detected by in situ hybridization. TAMs of invasive breast carcinomas and of DCIS possess significantly elevated uPAR levels compared with macrophages derived from normal breast tissue. CONCLUSIONS: activated macrophages with elevated uPAR levels belong to inflammatory areas in close vicinity of infiltrating and non-infiltrating (DCIS) tumor cells. Blood monocytes that possess elevated uPAR-levels may be selectively recruited from the bloodstream to inflammatory sites close to carcinoma cells, and/or breast cancer and precursor lesions may induce elevated uPAR-levels in TAMs by paracrine interactions. (+info)Primary tumour characteristics and axillary lymph node status in breast cancer. (6/1031)
This paper examines the correlation between axillary lymph node status and primary tumour characteristics in breast cancer and whether this can be used to select patients for axillary lymphadenectomy. The results are based on a retrospective analysis of 909 patients who underwent axillary dissection in our unit. Axillary lymph nodes containing metastases were found in 406 patients (44.7%), all with invasive carcinomas, but in none of the 37 carcinomas-in-situ. Nodal status was negative in all T1a tumours, but lymph node metastases were present in 16.3% and 35.7% of T1b and T1c tumours respectively. When histological grade was taken into account, positivity for grade I T1b and T1c tumours fell to 13.6% and 26.7% respectively. Lymph node metastases were found in 85% of patients with lymphovascular invasion in their tumours as compared to only 15.4% of those without and in 45.5% of oestrogen and progesterone receptor-positive tumours. When one or both hormone receptors were absent this figure was much higher. It appears that for T1a breast cancers axillary dissection is not necessary, whereas for T1b, T1c and grade I T2 tumours other histopathological parameters should be taken into consideration in deciding who should undergo axillary lymphadenectomy. (+info)Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. (7/1031)
Breast carcinoma is the most common malignant disease among women and the second most lethal one. In search for a better understanding of the role of cellular mediators in the progression of this disease, we investigated the potential involvement of the CC chemokine Regulated on Activation, Normal T Cell Expressed and Secreted (RANTES) in breast carcinoma progression. To this end, RANTES expression was determined in breast tumor cell lines and in sections of breast carcinomas, followed by analysis of the incidence and intensity of its expression in different stages of the disease. Our study reveals that high and physiologically relevant levels of RANTES are constitutively produced by T47D and MCF-7 breast tumor cell lines. Analysis of RANTES expression in sections of breast carcinomas demonstrates a high incidence of RANTES expression in epithelial tumor cells; the chemokine was expressed in 74% of the sections. RANTES expression was rarely detected in normal duct epithelial cells or in epithelial cells that constitute benign breast lumps, which were located in proximity to tumor cells. High incidence and intensity of RANTES expression were detected in sections of most of the patients with stage II and stage III of the disease (expression was detected in 83 and 83.3%, respectively), whereas RANTES was expressed at a lower incidence and intensity in sections of patients with stage I of breast carcinoma (55% of the cases). Most importantly, the expression of RANTES was minimally detected in sections of patients diagnosed with benign breast disorders and of women that underwent reduction mammoplasty (15.4% of the cases). These results indicate that the expression of RANTES is directly correlated with a more advanced stage of disease, suggesting that RANTES may be involved in breast cancer progression. Moreover, it is possible that in patients diagnosed with benign breast disorders, RANTES expression may be indicative of an ongoing, but as yet undetectable, malignant process. (+info)Prognosis in women with a carcinoma in situ of the breast: a population-based study in Sweden. (8/1031)
We studied the risk of invasive breast cancer and breast cancer death after a breast carcinoma in situ during a period when mammography screening became a nationwide practice and when breast conservation was introduced. In a study base including all 4661 women registered to the Swedish Cancer Registry for a first carcinoma in situ between 1960 and 1992, we selected a cohort of 3398 women diagnosed between 1980 and 1992. The recruitment period was chosen according to the reporting routines for the registry. The corrected survival was 97.4% after 10 years. The risk of invasive cancer was similar in the ipsilateral and contralateral breast. Women diagnosed between 1989 and 1992 ran a relative risk of 0.1 (95% confidence interval, 0.0-0.9) of dying of breast cancer, as compared with women diagnosed from 1980-1982. Residence in counties where mammography screening was available was associated with a relative risk of 0.2 (95% confidence interval, 0.0-2.1) for breast cancer death in the age groups screened. Screening mammography may have contributed to the improvement of prognosis over this time period. This study cannot distinguish between lead time effects and a "true" improvement in prognosis. The increased use of breast conservation was not associated with a worse prognosis in the group as a whole. The study indicates that at least 50% of invasive cancers occurring after treatment for in situ lesions may be new cancers. (+info)Intraductal carcinoma may or may not cause symptoms, and is usually detected by a mammogram. Treatment often involves surgery to remove the cancerous cells from the milk ducts. If left untreated, intraductal carcinoma may progress to more advanced breast cancer in some cases.
Intraductal carcinoma accounts for 20% of all breast cancers diagnosed each year in the United States, according to estimates from the American Cancer Society. The condition affects women of all ages, but is most common in postmenopausal women.
Papillomas are relatively common in women, especially during pregnancy or while taking hormone replacement therapy. They are usually diagnosed with imaging tests such as mammography or ultrasound. Treatment options for papillomas include observation, surgical removal, or laser ablation.
Papilloma, intraductal definition: A benign (non-cancerous) growth that occurs within a milk duct of the breast. See more at medical dictionary.reliantmedicalgroup.org
There are several subtypes of carcinoma, including:
1. Adenocarcinoma: This type of carcinoma originates in glandular cells, which produce fluids or mucus. Examples include breast cancer, prostate cancer, and colon cancer.
2. Squamous cell carcinoma: This type of carcinoma originates in squamous cells, which are found on the surface layers of skin and mucous membranes. Examples include head and neck cancers, cervical cancer, and anal cancer.
3. Basal cell carcinoma: This type of carcinoma originates in the deepest layer of skin, called the basal layer. It is the most common type of skin cancer and tends to grow slowly.
4. Neuroendocrine carcinoma: This type of carcinoma originates in cells that produce hormones and neurotransmitters. Examples include lung cancer, pancreatic cancer, and thyroid cancer.
5. Small cell carcinoma: This type of carcinoma is a highly aggressive form of lung cancer that spreads quickly to other parts of the body.
The signs and symptoms of carcinoma depend on the location and stage of the cancer. Some common symptoms include:
* A lump or mass
* Pain
* Skin changes, such as a new mole or a change in the color or texture of the skin
* Changes in bowel or bladder habits
* Abnormal bleeding
The diagnosis of carcinoma typically involves a combination of imaging tests, such as X-rays, CT scans, MRI scans, and PET scans, and a biopsy, which involves removing a small sample of tissue for examination under a microscope. Treatment options for carcinoma depend on the location and stage of the cancer and may include surgery, radiation therapy, chemotherapy, or a combination of these.
In conclusion, carcinoma is a type of cancer that originates in epithelial cells and can occur in various parts of the body. Early detection and treatment are important for improving outcomes.
References:
1. American Cancer Society. (2022). Carcinoma. Retrieved from
2. Mayo Clinic. (2022). Carcinoma. Retrieved from
3. MedlinePlus. (2022). Carcinoma. Retrieved from
Examples of 'Adenocarcinoma, Mucinous' in medical literature:
* The patient was diagnosed with adenocarcinoma, mucinous type, in their colon after undergoing a colonoscopy and biopsy. (From the Journal of Clinical Oncology)
* The patient had a history of adenocarcinoma, mucinous type, in their breast and was being monitored for potential recurrence. (From the Journal of Surgical Oncology)
* The tumor was found to be an adenocarcinoma, mucinous type, with a high grade and was treated with surgery and chemotherapy. (From the Journal of Gastrointestinal Oncology)
Synonyms for 'Adenocarcinoma, Mucinous' include:
* Mucinous adenocarcinoma
* Colon adenocarcinoma, mucinous type
* Rectal adenocarcinoma, mucinous type
* Adenocarcinoma of the colon and rectum, mucinous type.
The carcinogenesis process of PDAC usually starts with the accumulation of genetic mutations in the pancreatic duct cells, which progressively leads to the formation of a premalignant lesion called PanIN (pancreatic intraepithelial neoplasia). Over time, these lesions can develop into invasive adenocarcinoma, which is PDAC.
The main risk factor for developing PDAC is smoking, but other factors such as obesity, diabetes, and family history of pancreatic cancer also contribute to the development of the disease. Symptoms of PDAC are often non-specific and late-stage, which makes early diagnosis challenging.
The treatment options for PDAC are limited, and the prognosis is generally poor. Surgery is the only potentially curative treatment, but only a small percentage of patients are eligible for surgical resection due to the locally advanced nature of the disease at the time of diagnosis. Chemotherapy, radiation therapy, and targeted therapies are used to palliate symptoms and improve survival in non-surgical cases.
PDAC is an aggressive and lethal cancer, and there is a need for better diagnostic tools and more effective treatment strategies to improve patient outcomes.
The term "papillary" refers to the fact that the cancer cells grow in a finger-like shape, with each cell forming a small papilla (bump) on the surface of the tumor. APC is often slow-growing and may not cause any symptoms in its early stages.
APC is generally considered to be less aggressive than other types of cancer, such as ductal carcinoma in situ (DCIS) or invasive breast cancer. However, it can still spread to other parts of the body if left untreated. Treatment options for APC may include surgery, radiation therapy, and/or hormone therapy, depending on the location and stage of the cancer.
It's worth noting that APC is sometimes referred to as "papillary adenocarcinoma" or simply "papillary cancer." However, these terms are often used interchangeably with "adenocarcinoma, papillary" in medical literature and clinical practice.
SCC typically appears as a firm, flat, or raised bump on the skin, and may be pink, red, or scaly. The cancer cells are usually well-differentiated, meaning they resemble normal squamous cells, but they can grow rapidly and invade surrounding tissues if left untreated.
SCC is more common in fair-skinned individuals and those who spend a lot of time in the sun, as UV radiation can damage the skin cells and increase the risk of cancer. The cancer can also spread to other parts of the body, such as lymph nodes or organs, and can be life-threatening if not treated promptly and effectively.
Treatment for SCC usually involves surgery to remove the cancerous tissue, and may also include radiation therapy or chemotherapy to kill any remaining cancer cells. Early detection and treatment are important to improve outcomes for patients with SCC.
There are several risk factors for developing HCC, including:
* Cirrhosis, which can be caused by heavy alcohol consumption, viral hepatitis (such as hepatitis B and C), or fatty liver disease
* Family history of liver disease
* Chronic obstructive pulmonary disease (COPD)
* Diabetes
* Obesity
HCC can be challenging to diagnose, as the symptoms are non-specific and can be similar to those of other conditions. However, some common symptoms of HCC include:
* Yellowing of the skin and eyes (jaundice)
* Fatigue
* Loss of appetite
* Abdominal pain or discomfort
* Weight loss
If HCC is suspected, a doctor may perform several tests to confirm the diagnosis, including:
* Imaging tests, such as ultrasound, CT scan, or MRI, to look for tumors in the liver
* Blood tests to check for liver function and detect certain substances that are produced by the liver
* Biopsy, which involves removing a small sample of tissue from the liver to examine under a microscope
Once HCC is diagnosed, treatment options will depend on several factors, including the stage and location of the cancer, the patient's overall health, and their personal preferences. Treatment options may include:
* Surgery to remove the tumor or parts of the liver
* Ablation, which involves destroying the cancer cells using heat or cold
* Chemoembolization, which involves injecting chemotherapy drugs into the hepatic artery to reach the cancer cells
* Targeted therapy, which uses drugs or other substances to target specific molecules that are involved in the growth and spread of the cancer
Overall, the prognosis for HCC is poor, with a 5-year survival rate of approximately 20%. However, early detection and treatment can improve outcomes. It is important for individuals at high risk for HCC to be monitored regularly by a healthcare provider, and to seek medical attention if they experience any symptoms.
Also known as CIS.
Pancreatic adenocarcinoma is the most common type of malignant pancreatic neoplasm and accounts for approximately 85% of all pancreatic cancers. It originates in the glandular tissue of the pancreas and has a poor prognosis, with a five-year survival rate of less than 10%.
Pancreatic neuroendocrine tumors (PNETs) are less common but more treatable than pancreatic adenocarcinoma. These tumors originate in the hormone-producing cells of the pancreas and can produce excess hormones that cause a variety of symptoms, such as diabetes or high blood sugar. PNETs are classified into two main types: functional and non-functional. Functional PNETs produce excess hormones and are more aggressive than non-functional tumors.
Other rare types of pancreatic neoplasms include acinar cell carcinoma, ampullary cancer, and oncocytic pancreatic neuroendocrine tumors. These tumors are less common than pancreatic adenocarcinoma and PNETs but can be equally aggressive and difficult to treat.
The symptoms of pancreatic neoplasms vary depending on the type and location of the tumor, but they often include abdominal pain, weight loss, jaundice, and fatigue. Diagnosis is typically made through a combination of imaging tests such as CT scans, endoscopic ultrasound, and biopsy. Treatment options for pancreatic neoplasms depend on the type and stage of the tumor but may include surgery, chemotherapy, radiation therapy, or a combination of these.
Prognosis for patients with pancreatic neoplasms is generally poor, especially for those with advanced stages of disease. However, early detection and treatment can improve survival rates. Research into the causes and mechanisms of pancreatic neoplasms is ongoing, with a focus on developing new and more effective treatments for these devastating diseases.
Characteristics:
* Mucinous cystadenomas are typically slow-growing and asymptomatic, but can occasionally cause pelvic pain or discomfort due to their size.
* They are usually unilateral (affecting one ovary), but can rarely occur bilaterally (affecting both ovaries).
* The tumor is composed of mucin-secreting epithelial cells that form glands or cysts within a fibrous stroma.
* Cystadenomas are typically encapsulated, but can rarely become invasive and infiltrate surrounding tissues.
* Mucinous cystadenomas are usually small (less than 5 cm in diameter), but can occasionally be larger.
Diagnosis:
* Imaging studies such as ultrasound or computed tomography (CT) scans may be used to detect the presence of a cystic mass in the ovary, but a definitive diagnosis is usually made through surgical exploration and histopathologic examination of the tumor tissue.
* A preoperative diagnosis of mucinous cystadenoma can be challenging, as the imaging features are not specific and may resemble other ovarian tumors, such as serous cystadenomas or borderline tumors.
Treatment:
* Surgical excision is the primary treatment for mucinous cystadenoma, and the procedure is usually performed through a laparotomy or laparoscopy.
* The surgical approach depends on the size and location of the tumor, as well as the patient's age and fertility status.
* In some cases, the tumor may be removed through a staged approach, with initial cytoreduction followed by chemotherapy or radiation therapy to shrink the remaining tumor burden.
Prognosis:
* Mucinous cystadenoma is generally considered a benign tumor, and the prognosis is excellent for most patients.
* The overall survival rate is high, and the majority of patients can expect to be cured with surgical excision alone.
* However, in rare cases, mucinous cystadenoma can recur or progress to more aggressive types of ovarian cancer, such as serous carcinoma.
Follow-up:
* After surgical excision, patients with mucinous cystadenoma should be followed up with regular pelvic examinations, imaging studies, and serum CA 125 levels to monitor for any signs of recurrence or progression.
* The frequency of follow-up appointments may vary depending on the patient's age, tumor size, and other factors, but annual pelvic examinations and imaging studies are generally recommended for at least 5 years after surgery.
References:
1. Kurman RJ, et al. The origin and pathology of ovarian borderline tumors. International Journal of Gynecological Pathology. 2014;33(2):197-211.
2. Di Cerbo A, et al. Mucinous cystadenoma of the ovary: a review of the literature. Journal of Obstetrics and Gynaecology Canada. 2018;40(6):753-763.
3. Chung H, et al. The clinicopathological features and prognosis of mucinous cystadenoma of the ovary: a systematic review and meta-analysis. Gynecologic Oncology Reports. 2018;20:135-143.
Cystic neoplasms are fluid-filled sacs that grow in the body. They can be benign or malignant and can arise from a variety of tissues, including the ovaries, pancreas, and lungs. Mucinous neoplasms are tumors that produce mucin, a type of protein found in mucus. These tumors can occur in the breast, ovary, or colon, and are often benign.
Serous neoplasms are tumors that arise from the serous membranes, which are the thin layers of tissue that line the cavities of the body. Examples of serous neoplasms include ovarian cancer and mesothelioma. These tumors can be benign or malignant.
In summary, neoplasms, cystic, mucinous, and serous are different types of tumors that can occur in various organs and tissues throughout the body. While they can be benign, many of these tumors are malignant and can spread to other parts of the body if left untreated.
The exact cause of ductal carcinoma is unknown, but certain risk factors such as family history, genetics, hormone replacement therapy, obesity, and delayed childbearing have been linked to its development. Early detection through mammography and breast self-examination can improve survival rates, which are generally high for women diagnosed with this type of cancer if caught early. Treatment typically involves surgery to remove the tumor (lumpectomy or mastectomy), followed by radiation therapy and/or chemotherapy.
Bile duct neoplasms refer to abnormal growths or tumors that occur in the bile ducts, which are the tubes that carry bile from the liver and gallbladder to the small intestine. Bile duct neoplasms can be benign (non-cancerous) or malignant (cancerous).
Types of Bile Duct Neoplasms:
There are several types of bile duct neoplasms, including:
1. Bile duct adenoma: A benign tumor that grows in the bile ducts.
2. Bile duct carcinoma: A malignant tumor that grows in the bile ducts and can spread to other parts of the body.
3. Cholangiocarcinoma: A rare type of bile duct cancer that originates in the cells lining the bile ducts.
4. Gallbladder cancer: A type of cancer that occurs in the gallbladder, which is a small organ located under the liver that stores bile.
Causes and Risk Factors:
The exact cause of bile duct neoplasms is not known, but there are several risk factors that may increase the likelihood of developing these tumors, including:
1. Age: Bile duct neoplasms are more common in people over the age of 50.
2. Gender: Women are more likely to develop bile duct neoplasms than men.
3. Family history: People with a family history of bile duct cancer or other liver diseases may be at increased risk.
4. Previous exposure to certain chemicals: Exposure to certain chemicals, such as thorium, has been linked to an increased risk of developing bile duct neoplasms.
Symptoms:
The symptoms of bile duct neoplasms can vary depending on the location and size of the tumor. Some common symptoms include:
1. Yellowing of the skin and eyes (jaundice)
2. Fatigue
3. Loss of appetite
4. Nausea and vomiting
5. Abdominal pain or discomfort
6. Weight loss
7. Itching all over the body
8. Dark urine
9. Pale stools
Diagnosis:
Diagnosis of bile duct neoplasms typically involves a combination of imaging tests and biopsy. The following tests may be used to diagnose bile duct neoplasms:
1. Ultrasound: This non-invasive test uses high-frequency sound waves to create images of the liver and bile ducts.
2. Computed tomography (CT) scan: This imaging test uses X-rays and computer technology to create detailed images of the liver and bile ducts.
3. Magnetic resonance imaging (MRI): This test uses a strong magnetic field and radio waves to create detailed images of the liver and bile ducts.
4. Endoscopic ultrasound: This test involves inserting an endoscope (a thin, flexible tube with a small ultrasound probe) into the bile ducts through the mouth or stomach to obtain images and samples of the bile ducts.
5. Biopsy: A biopsy may be performed during an endoscopic ultrasound or during surgery to remove the tumor. The sample is then examined under a microscope for cancer cells.
Treatment:
The treatment of bile duct neoplasms depends on several factors, including the type and stage of the cancer, the patient's overall health, and the patient's preferences. The following are some common treatment options for bile duct neoplasms:
1. Surgery: Surgery may be performed to remove the tumor or a portion of the bile duct. This may involve a Whipple procedure (a surgical procedure to remove the head of the pancreas, the gallbladder, and a portion of the bile duct), a bile duct resection, or a liver transplant.
2. Chemotherapy: Chemotherapy may be used before or after surgery to shrink the tumor and kill any remaining cancer cells.
3. Radiation therapy: Radiation therapy may be used to destroy cancer cells that cannot be removed by surgery or to relieve symptoms such as pain or blockage of the bile duct.
4. Stent placement: A stent may be placed in the bile duct to help keep it open and improve blood flow to the liver.
5. Ablation therapy: Ablation therapy may be used to destroy cancer cells by freezing or heating them with a probe inserted through an endoscope.
6. Targeted therapy: Targeted therapy may be used to treat certain types of bile duct cancer, such as cholangiocarcinoma, by targeting specific molecules that promote the growth and spread of the cancer cells.
7. Clinical trials: Clinical trials are research studies that evaluate new treatments for bile duct neoplasms. These may be an option for patients who have not responded to other treatments or who have advanced cancer.
1. Pancreatic mucinous cysts: These are the most common type of pancreatic cyst and are usually benign (non-cancerous). They can range in size from a few millimeters to several centimeters and may contain mucin, a type of protein.
2. Pancreatic pseudocysts: These are fluid-filled sacs that develop after pancreatitis, an inflammation of the pancreas. Pseudocysts are usually more solid than mucinous cysts and can be filled with pancreatic tissue, blood, and other debris.
3. Intraductal papillary mucinous neoplasms (IPMNs): These are precancerous growths that develop in the pancreatic ducts and can progress to pancreatic cancer if left untreated.
4. Other rare types of pancreatic cysts include serous cystic neoplasms, clear cell cysts, and oncocytic cysts.
Pancreatic cysts may not cause any symptoms in their early stages, but as they grow, they can press on nearby organs and cause pain, nausea, vomiting, and other digestive problems. Large cysts can also block the pancreatic ducts, leading to pancreatitis.
Diagnosis of pancreatic cysts typically involves imaging tests such as CT scans, MRI scans, or endoscopic ultrasound. Fine-needle aspiration (FNA) biopsy may also be performed to collect a sample of the cyst fluid for further examination.
Treatment of pancreatic cysts depends on their type, size, and location. Small, benign cysts may not require treatment and can be monitored with regular imaging tests. Larger cysts may need to be drained or removed surgically, especially if they are causing symptoms or increasing in size.
It is essential for individuals with a history of pancreatic cysts to follow up regularly with their healthcare provider to monitor for any changes in the cysts and to ensure early detection of any potential cancerous changes.
Liver neoplasms, also known as liver tumors or hepatic tumors, are abnormal growths of tissue in the liver. These growths can be benign (non-cancerous) or malignant (cancerous). Malignant liver tumors can be primary, meaning they originate in the liver, or metastatic, meaning they spread to the liver from another part of the body.
There are several types of liver neoplasms, including:
1. Hepatocellular carcinoma (HCC): This is the most common type of primary liver cancer and arises from the main cells of the liver (hepatocytes). HCC is often associated with cirrhosis and can be caused by viral hepatitis or alcohol abuse.
2. Cholangiocarcinoma: This type of cancer arises from the cells lining the bile ducts within the liver (cholangiocytes). Cholangiocarcinoma is rare and often diagnosed at an advanced stage.
3. Hemangiosarcoma: This is a rare type of cancer that originates in the blood vessels of the liver. It is most commonly seen in dogs but can also occur in humans.
4. Fibromas: These are benign tumors that arise from the connective tissue of the liver (fibrocytes). Fibromas are usually small and do not spread to other parts of the body.
5. Adenomas: These are benign tumors that arise from the glandular cells of the liver (hepatocytes). Adenomas are usually small and do not spread to other parts of the body.
The symptoms of liver neoplasms vary depending on their size, location, and whether they are benign or malignant. Common symptoms include abdominal pain, fatigue, weight loss, and jaundice (yellowing of the skin and eyes). Diagnosis is typically made through a combination of imaging tests such as CT scans, MRI scans, and ultrasound, and a biopsy to confirm the presence of cancer cells.
Treatment options for liver neoplasms depend on the type, size, location, and stage of the tumor, as well as the patient's overall health. Surgery may be an option for some patients with small, localized tumors, while others may require chemotherapy or radiation therapy to shrink the tumor before surgery can be performed. In some cases, liver transplantation may be necessary.
Prognosis for liver neoplasms varies depending on the type and stage of the cancer. In general, early detection and treatment improve the prognosis, while advanced-stage disease is associated with a poorer prognosis.
There are different types of Breast Neoplasms such as:
1. Fibroadenomas: These are benign tumors that are made up of glandular and fibrous tissues. They are usually small and round, with a smooth surface, and can be moved easily under the skin.
2. Cysts: These are fluid-filled sacs that can develop in both breast tissue and milk ducts. They are usually benign and can disappear on their own or be drained surgically.
3. Ductal Carcinoma In Situ (DCIS): This is a precancerous condition where abnormal cells grow inside the milk ducts. If left untreated, it can progress to invasive breast cancer.
4. Invasive Ductal Carcinoma (IDC): This is the most common type of breast cancer and starts in the milk ducts but grows out of them and invades surrounding tissue.
5. Invasive Lobular Carcinoma (ILC): It originates in the milk-producing glands (lobules) and grows out of them, invading nearby tissue.
Breast Neoplasms can cause various symptoms such as a lump or thickening in the breast or underarm area, skin changes like redness or dimpling, change in size or shape of one or both breasts, discharge from the nipple, and changes in the texture or color of the skin.
Treatment options for Breast Neoplasms may include surgery such as lumpectomy, mastectomy, or breast-conserving surgery, radiation therapy which uses high-energy beams to kill cancer cells, chemotherapy using drugs to kill cancer cells, targeted therapy which uses drugs or other substances to identify and attack cancer cells while minimizing harm to normal cells, hormone therapy, immunotherapy, and clinical trials.
It is important to note that not all Breast Neoplasms are cancerous; some are benign (non-cancerous) tumors that do not spread or grow.
1. Tumor size and location: Larger tumors that have spread to nearby tissues or organs are generally considered more invasive than smaller tumors that are confined to the original site.
2. Cellular growth patterns: The way in which cancer cells grow and divide can also contribute to the overall invasiveness of a neoplasm. For example, cells that grow in a disorganized or chaotic manner may be more likely to invade surrounding tissues.
3. Mitotic index: The mitotic index is a measure of how quickly the cancer cells are dividing. A higher mitotic index is generally associated with more aggressive and invasive cancers.
4. Necrosis: Necrosis, or the death of cells, can be an indication of the level of invasiveness of a neoplasm. The presence of significant necrosis in a tumor is often a sign that the cancer has invaded surrounding tissues and organs.
5. Lymphovascular invasion: Cancer cells that have invaded lymphatic vessels or blood vessels are considered more invasive than those that have not.
6. Perineural invasion: Cancer cells that have invaded nerve fibers are also considered more invasive.
7. Histological grade: The histological grade of a neoplasm is a measure of how abnormal the cancer cells look under a microscope. Higher-grade cancers are generally considered more aggressive and invasive than lower-grade cancers.
8. Immunohistochemical markers: Certain immunohistochemical markers, such as Ki-67, can be used to evaluate the proliferative activity of cancer cells. Higher levels of these markers are generally associated with more aggressive and invasive cancers.
Overall, the degree of neoplasm invasiveness is an important factor in determining the likelihood of the cancer spreading to other parts of the body (metastasizing) and in determining the appropriate treatment strategy for the patient.
The term "cystadenoma" refers to a benign tumor that grows from glandular tissue, and "serous" indicates that the tumor is derived from the serous (fluid-producing) cells of the ovary. The tumor typically forms a cystic mass filled with a clear or cloudy liquid, and can range in size from small to several centimeters in diameter.
CS usually affects women during their reproductive years, and the peak incidence is between 20 and 40 years of age. Symptoms may include abdominal pain, bloating, and vaginal bleeding, but many cases are asymptomatic and are detected incidentally during pelvic examination or imaging studies.
The exact cause of CS is not known, but it is believed to be related to genetic mutations and hormonal factors. The tumor cells have a characteristic immunophenotype, with expression of markers such as cytokeratin 7 and epidermal growth factor receptor (EGFR).
The diagnosis of CS is based on a combination of imaging studies, such as ultrasound and computed tomography (CT), and histopathological examination of tissue samples obtained through laparoscopy or surgery. Treatment options for CS include watchful waiting, fertility-sparing surgery, and total hysterectomy with bilateral salpingo-oophorectomy (THBSO).
In summary, cystadenoma, serous is a common type of benign ovarian tumor that originates from the serous cells of the ovary. It typically affects women during their reproductive years and can cause symptoms such as abdominal pain and vaginal bleeding. The exact cause is not known, but it is believed to be related to genetic mutations and hormonal factors. Diagnosis is based on a combination of imaging studies and histopathological examination of tissue samples, and treatment options include watchful waiting, fertility-sparing surgery, and total hysterectomy with bilateral salpingo-oophorectomy.
BCC usually appears as a flesh-colored or pink bump, often with small blood vessels on the surface. It may also be flat and scaly, or have a waxy appearance. In rare cases, BCC can grow deep into the skin and cause damage to surrounding tissue.
Although BCC is not as aggressive as other types of skin cancer, such as melanoma, it can still cause significant damage if left untreated. Treatment options for BCC include topical creams, surgical excision, and Mohs microscopic surgery.
Preventative measures against BCC include protecting the skin from the sun, using sunscreen with a high SPF, and avoiding prolonged exposure to UV radiation. Early detection and treatment are key in managing this condition.
Adenocarcinoma is a term used to describe a variety of different types of cancer that arise in glandular tissue, including:
1. Colorectal adenocarcinoma (cancer of the colon or rectum)
2. Breast adenocarcinoma (cancer of the breast)
3. Prostate adenocarcinoma (cancer of the prostate gland)
4. Pancreatic adenocarcinoma (cancer of the pancreas)
5. Lung adenocarcinoma (cancer of the lung)
6. Thyroid adenocarcinoma (cancer of the thyroid gland)
7. Skin adenocarcinoma (cancer of the skin)
The symptoms of adenocarcinoma depend on the location of the cancer and can include:
1. Blood in the stool or urine
2. Abdominal pain or discomfort
3. Changes in bowel habits
4. Unusual vaginal bleeding (in the case of endometrial adenocarcinoma)
5. A lump or thickening in the breast or elsewhere
6. Weight loss
7. Fatigue
8. Coughing up blood (in the case of lung adenocarcinoma)
The diagnosis of adenocarcinoma is typically made through a combination of imaging tests, such as CT scans, MRI scans, and PET scans, and a biopsy, which involves removing a sample of tissue from the affected area and examining it under a microscope for cancer cells.
Treatment options for adenocarcinoma depend on the location of the cancer and can include:
1. Surgery to remove the tumor
2. Chemotherapy, which involves using drugs to kill cancer cells
3. Radiation therapy, which involves using high-energy X-rays or other particles to kill cancer cells
4. Targeted therapy, which involves using drugs that target specific molecules on cancer cells to kill them
5. Immunotherapy, which involves using drugs that stimulate the immune system to fight cancer cells.
The prognosis for adenocarcinoma is generally good if the cancer is detected and treated early, but it can be more challenging to treat if the cancer has spread to other parts of the body.
Mucinous cystadenocarcinoma is a type of primary ovarian cancer, meaning it originates in the ovary rather than spreading from another part of the body. It accounts for only about 2% to 5% of all ovarian cancers and tends to affect women in their later reproductive years or postmenopausal age.
The exact cause of mucinous cystadenocarcinoma is not known, but it may be related to genetic mutations or hormonal imbalances. Women with a family history of ovarian cancer or those with certain inherited genetic syndromes are at higher risk for developing this type of cancer.
The diagnosis of mucinous cystadenocarcinoma is based on a combination of imaging studies, such as ultrasound and computed tomography (CT) scans, and tissue biopsy. Treatment typically involves surgery to remove the affected ovary and any other involved organs or tissues, followed by chemotherapy or radiation therapy to reduce the risk of recurrence. Prognosis for this type of cancer is generally good if it is detected early and treated appropriately.
In summary, mucinous cystadenocarcinoma is a rare type of ovarian cancer that develops in the mucin-secreting cells of the ovary. It tends to affect older women and may be related to genetic or hormonal factors. Diagnosis is based on imaging studies and tissue biopsy, and treatment typically involves surgery and chemotherapy or radiation therapy. Prognosis is generally good if caught early.
Example sentence: "After undergoing surgery to remove the papillary cystadenoma, the patient made a full recovery."
Carcinoma, lobular (also known as lobular carcinoma in situ or LCIS) is a type of cancer that originates in the milk-producing glands (lobules) of the breast. It is a precancerous condition that can progress to invasive breast cancer if left untreated.
Precancerous changes occur within the lobules, leading to an abnormal growth of cells that can eventually break through the basement membrane and invade surrounding tissues. The risk of developing invasive breast cancer is increased in individuals with LCIS, especially if there are multiple areas of involvement.
Diagnosis is typically made through a combination of clinical breast examination, mammography, and histopathological analysis of a biopsy sample. Treatment options for LCIS include close surveillance, surgery, or radiation therapy, depending on the extent of the condition and the individual patient's risk factors.
Medical Specialty:
The medical specialty that deals with carcinoma, lobular is breast surgical oncology. Breast surgical oncologists are trained to diagnose and treat all types of breast cancer, including ductal and lobular carcinomas. They work in collaboration with other healthcare professionals, such as radiation oncologists and medical oncologists, to develop a comprehensive treatment plan for each patient.
Other relevant information:
* Lobular carcinoma in situ (LCIS) is a precancerous condition that affects the milk-producing glands (lobules) of the breast.
* It is estimated that 10-15% of all breast cancers are derived from LCIS.
* Women with a history of LCIS have a higher risk of developing invasive breast cancer in the future.
* The exact cause of LCIS is not fully understood, but it is thought to be linked to hormonal and genetic factors.
Transitional cell carcinoma typically affects older adults, with the average age at diagnosis being around 70 years. Men are more likely to be affected than women, and the risk of developing TCC increases with age and exposure to certain environmental factors such as smoking and exposure to certain chemicals.
The symptoms of TCC can vary depending on the location and stage of the cancer, but may include:
* Blood in the urine (hematuria)
* Painful urination
* Frequent urination
* Pain in the lower abdomen or back
If left untreated, TCC can spread to other parts of the body, including the lymph nodes, liver, and bones. Treatment options for TCC may include surgery, chemotherapy, and immunotherapy, and the prognosis depends on the stage and location of the cancer at the time of diagnosis.
Preventive measures to reduce the risk of developing TCC include maintaining a healthy diet and lifestyle, avoiding smoking and excessive alcohol consumption, and regular screening for bladder cancer. Early detection and treatment can improve the prognosis for patients with TCC.
Multiple primary neoplasms can arise in different organs or tissues throughout the body, such as the breast, colon, prostate, lung, or skin. Each tumor is considered a separate entity, with its own unique characteristics, including size, location, and aggressiveness. Treatment for multiple primary neoplasms typically involves surgery, chemotherapy, radiation therapy, or a combination of these modalities.
The diagnosis of multiple primary neoplasms can be challenging due to the overlapping symptoms and radiological findings between the different tumors. Therefore, it is essential to have a thorough clinical evaluation and diagnostic workup to rule out other possible causes of the symptoms and confirm the presence of multiple primary neoplasms.
Multiple primary neoplasms are more common than previously thought, with an estimated prevalence of 2% to 5% in some populations. The prognosis for patients with multiple primary neoplasms varies depending on the location, size, and aggressiveness of each tumor, as well as the patient's overall health status.
It is important to note that multiple primary neoplasms are not the same as metastatic cancer, in which a single primary tumor spreads to other parts of the body. Multiple primary neoplasms are distinct tumors that arise independently from different primary sites within the body.
The risk factors for developing bronchogenic carcinoma include smoking, exposure to secondhand smoke, exposure to radon gas, asbestos, and certain industrial chemicals, as well as a family history of lung cancer. Symptoms of bronchogenic carcinoma can include coughing, chest pain, difficulty breathing, fatigue, weight loss, and coughing up blood.
Bronchogenic carcinoma is diagnosed through a combination of imaging tests such as chest x-rays, computed tomography (CT) scans, and positron emission tomography (PET) scans, as well as biopsy. Treatment options for bronchogenic carcinoma can include surgery, radiation therapy, chemotherapy, or a combination of these. The prognosis for bronchogenic carcinoma is generally poor, with a five-year survival rate of about 18%.
Prevention is the best approach to managing bronchogenic carcinoma, and this includes quitting smoking, avoiding exposure to secondhand smoke and other risk factors, and getting regular screenings if you are at high risk. Early detection and treatment can improve survival rates for patients with bronchogenic carcinoma, so it is important to seek medical attention if symptoms persist or worsen over time.
This cancer is known for its aggressive behavior and early metastasis to regional lymph nodes, bones, and distant organs such as the liver and lungs. The prognosis is generally poor, with a 5-year survival rate of about 50%. The treatment options include surgery, radiation therapy, and chemotherapy, and the choice of treatment depends on the stage and location of the tumor.
Adenoid cystic carcinoma is also known as adenoid cystic cancer, cylindromatosis, or basaloid squamous cell carcinoma. It is a rare malignancy that requires specialized knowledge and management by head and neck surgeons and oncologists.
Examples of precancerous conditions include:
1. Dysplasia: This is a condition where abnormal cells are present in the tissue, but have not yet invaded surrounding tissues. Dysplasia can be found in organs such as the cervix, colon, and breast.
2. Carcinoma in situ (CIS): This is a condition where cancer cells are present in the tissue, but have not yet invaded surrounding tissues. CIS is often found in organs such as the breast, prostate, and cervix.
3. Atypical hyperplasia: This is a condition where abnormal cells are present in the tissue, but they are not yet cancerous. Atypical hyperplasia can be found in organs such as the breast and uterus.
4. Lobular carcinoma in situ (LCIS): This is a condition where cancer cells are present in the milk-producing glands of the breasts, but have not yet invaded surrounding tissues. LCIS is often found in both breasts and can increase the risk of developing breast cancer.
5. Adenomas: These are small growths on the surface of the colon that can become malignant over time if left untreated.
6. Leukoplakia: This is a condition where thick, white patches develop on the tongue or inside the mouth. Leukoplakia can be a precancerous condition and may increase the risk of developing oral cancer.
7. Oral subsquamous carcinoma: This is a type of precancerous lesion that develops in the mouth and can progress to squamous cell carcinoma if left untreated.
8. Cervical intraepithelial neoplasia (CIN): This is a condition where abnormal cells are present on the surface of the cervix, but have not yet invaded surrounding tissues. CIN can progress to cancer over time if left untreated.
9. Vulvar intraepithelial neoplasia (VIN): This is a condition where abnormal cells are present on the vulva, but have not yet invaded surrounding tissues. VIN can progress to cancer over time if left untreated.
10. Penile intraepithelial neoplasia (PIN): This is a condition where abnormal cells are present on the penis, but have not yet invaded surrounding tissues. PIN can progress to cancer over time if left untreated.
It is important to note that not all precancerous conditions will develop into cancer, and some may resolve on their own without treatment. However, it is important to follow up with a healthcare provider to monitor any changes and determine the best course of treatment.
Epidemiology:
* Incidence: Small cell carcinoma (SCC) accounts for approximately 10%-15% of all skin cancers, but it is more common in certain populations such as fair-skinned individuals and those with a history of sun exposure.
* Prevalence: The prevalence of SCC is difficult to determine due to its rarity, but it is believed to be more common in certain geographic regions such as Australia and New Zealand.
Clinical features:
* Appearance: Small cell carcinoma usually appears as a firm, shiny nodule or plaque on sun-exposed areas of the skin, such as the face, ears, lips, and hands. It can also occur in other parts of the body, including the mucous membranes.
* Color: The color of SCC can range from pink to red to purple, and it may be covered with a crust or scab.
* Dimensions: SCC usually measures between 1-5 cm in diameter, but it can be larger in some cases.
* Surface: The surface of SCC may be smooth or rough, and it may have a "pearly" appearance due to the presence of small, white, and shiny nodules called "heidlebergs."
Differential diagnosis:
* Other types of skin cancer, such as basal cell carcinoma and squamous cell carcinoma.
* Other diseases that can cause similar symptoms and appearance, such as psoriasis, eczema, and actinic keratosis.
Treatment:
* Surgical excision: Small cell carcinoma is usually treated with surgical excision, which involves removing the tumor and some surrounding tissue.
* Radiation therapy: In some cases, radiation therapy may be used after surgical excision to ensure that all cancer cells are eliminated.
* Topical treatments: For more superficial SCC, topical treatments such as imiquimod cream or podofilox solution may be effective.
Prognosis:
* The prognosis for small cell carcinoma is generally good if it is detected and treated early.
* However, if left untreated, SCC can invade surrounding tissues and organs, leading to serious complications and potentially fatal outcomes.
Complications:
* Invasion of surrounding tissues and organs.
* Spread of cancer cells to other parts of the body (metastasis).
* Scarring and disfigurement.
* Infection and inflammation.
Characteristics of Medullary Carcinoma:
1. Location: Medullary carcinoma typically arises in the inner substance of the breast, near the milk ducts and blood vessels.
2. Growth pattern: The cancer cells grow in a nodular or sheet-like pattern, with a clear boundary between the tumor and the surrounding normal tissue.
3. Cellular features: The cancer cells are typically large and polygonal, with prominent nucleoli and a pale, pinkish cytoplasm.
4. Lymphocytic infiltration: There is often a significant amount of lymphocytic infiltration surrounding the tumor, which can give it a "spiculated" or "heterogeneous" appearance.
5. Grade: Medullary carcinoma is generally a low-grade cancer, meaning that the cells are slow-growing and less aggressive than those of other types of breast cancer.
6. Hormone receptors: Medullary carcinoma is often hormone receptor-positive, meaning that the cancer cells have estrogen or progesterone receptors on their surface.
7. Her2 status: The cancer cells are typically Her2-negative, meaning that they do not overexpress the Her2 protein.
Prognosis and Treatment of Medullary Carcinoma:
The prognosis for medullary carcinoma is generally good, as it tends to be a slow-growing and less aggressive type of breast cancer. The 5-year survival rate for medullary carcinoma is around 80-90%.
Treatment for medullary carcinoma typically involves surgery, such as a lumpectomy or mastectomy, followed by radiation therapy and/or hormone therapy. Chemotherapy is sometimes used in addition to these treatments, especially if the cancer has spread to the lymph nodes or other parts of the body.
It's important for women with medullary carcinoma to work closely with their healthcare team to develop a personalized treatment plan that takes into account their unique needs and circumstances. With appropriate treatment, many women with medullary carcinoma can achieve long-term survival and a good quality of life.
Cystadenocarcinoma can occur in various parts of the body, but it is most common in the ovary and breast. In the ovary, it is the most common type of ovarian cancer and accounts for about 70% of all ovarian cancers. In the breast, it is a rare type of breast cancer, accounting for less than 5% of all breast cancers.
The symptoms of cystadenocarcinoma can vary depending on the location of the tumor, but they may include:
* Abnormal vaginal bleeding or discharge
* Pelvic pain or discomfort
* Abdominal swelling or bloating
* Painful urination
* Weakness and fatigue
Cystadenocarcinoma is diagnosed through a combination of imaging tests, such as ultrasound, CT scan, or MRI, and biopsy. Treatment options may include surgery, chemotherapy, and/or radiation therapy, depending on the stage and location of the cancer.
The prognosis for cystadenocarcinoma depends on the stage of the cancer at the time of diagnosis. In general, early detection and treatment improve the chances of a successful outcome. However, cystadenocarcinoma can be an aggressive cancer, and the 5-year survival rate is lower for advanced stages of the disease.
In summary, cystadenocarcinoma is a type of cancer that arises from glandular cells in various parts of the body, but most commonly in the ovary and breast. It can cause a range of symptoms and is diagnosed through imaging tests and biopsy. Treatment options include surgery, chemotherapy, and/or radiation therapy, and the prognosis depends on the stage of the cancer at the time of diagnosis.
Note: The above definition is intended to provide a general understanding of the term 'Cystadenoma' and should not be considered as medical advice or diagnosis. If you have any concerns about your health, please consult a qualified medical professional for proper evaluation and care.
Lymphatic metastasis occurs when cancer cells enter the lymphatic vessels and are carried through the lymphatic system to other parts of the body. This can happen through several mechanisms, including:
1. Direct invasion: Cancer cells can invade the nearby lymphatic vessels and spread through them.
2. Lymphatic vessel embolization: Cancer cells can block the flow of lymphatic fluid and cause the formation of a clot-like structure, which can trap cancer cells and allow them to grow.
3. Lymphatic vessel invasion: Cancer cells can infiltrate the walls of lymphatic vessels and spread through them.
Lymphatic metastasis is a common mechanism for the spread of cancer, particularly in the breast, melanoma, and other cancers that have a high risk of lymphatic invasion. The presence of lymphatic metastasis in a patient's body can indicate a more aggressive cancer and a poorer prognosis.
Treatment for lymphatic metastasis typically involves a combination of surgery, chemotherapy, and radiation therapy. Surgery may be used to remove any affected lymph nodes or other tumors that have spread through the lymphatic system. Chemotherapy may be used to kill any remaining cancer cells, while radiation therapy may be used to shrink the tumors and relieve symptoms.
In summary, lymphatic metastasis is a common mechanism for the spread of cancer through the body, particularly in cancers that originate in organs with a high lymphatic drainage. Treatment typically involves a combination of surgery, chemotherapy, and radiation therapy to remove or shrink the tumors and relieve symptoms.
There are several causes of pancreatitis, including:
1. Gallstones: These can block the pancreatic duct, causing inflammation.
2. Alcohol consumption: Heavy alcohol use can damage the pancreas and lead to inflammation.
3. High triglycerides: Elevated levels of triglycerides in the blood can cause pancreatitis.
4. Infections: Viral or bacterial infections can infect the pancreas and cause inflammation.
5. Genetic factors: Some people may be more susceptible to pancreatitis due to inherited genetic mutations.
6. Pancreatic trauma: Physical injury to the pancreas can cause inflammation.
7. Certain medications: Some medications, such as certain antibiotics and chemotherapy drugs, can cause pancreatitis as a side effect.
Symptoms of pancreatitis may include:
1. Abdominal pain
2. Nausea and vomiting
3. Fever
4. Diarrhea or bloating
5. Weight loss
6. Loss of appetite
Treatment for pancreatitis depends on the underlying cause and the severity of the condition. In some cases, hospitalization may be necessary to manage symptoms and address any complications. Treatment options may include:
1. Pain management: Medications such as nonsteroidal anti-inflammatory drugs (NSAIDs) or opioids may be used to manage abdominal pain.
2. Fluid replacement: Intravenous fluids may be given to replace lost fluids and electrolytes.
3. Antibiotics: If the pancreatitis is caused by an infection, antibiotics may be prescribed to treat the infection.
4. Nutritional support: Patients with pancreatitis may require nutritional support to ensure they are getting enough calories and nutrients.
5. Pancreatic enzyme replacement therapy: In some cases, pancreatic enzyme replacement therapy may be necessary to help the body digest food.
6. Surgery: In severe cases of pancreatitis, surgery may be necessary to remove damaged tissue or repair damaged blood vessels.
It is important to seek medical attention if you experience persistent abdominal pain or other symptoms of pancreatitis, as early treatment can help prevent complications and improve outcomes.
Definition:
A type of cancer that arises from cells of the neuroendocrine system, which are cells that produce hormones and neurotransmitters. These tumors can occur in various parts of the body, such as the lungs, digestive tract, and pancreas. They tend to grow slowly and can produce excess hormones or neurotransmitters, leading to a variety of symptoms. Carcinoma, neuroendocrine tumors are relatively rare but are becoming more commonly diagnosed.
Synonyms:
* Neuroendocrine carcinoma
* Neuroendocrine tumor
* Carcinoid tumor
Note: The term "carcinoma" refers to a type of cancer that arises from epithelial cells, while the term "neuroendocrine" refers to the fact that these tumors originate in cells of the neuroendocrine system.
Translation:
English: Neuroendocrine carcinoma
German: Neuroendokrines Karzinom
French: Tumeur carcinoïde neuroendocrine
Spanish: Carcinoma neuendocrino
Italian: Carcinoma neuroendocrino
Most nasopharyngeal neoplasms are rare and tend to affect children and young adults more frequently than older adults. The most common types of nasopharyngeal neoplasms include:
1. Nasopharyngeal carcinoma (NPC): This is the most common type of malignant nasopharyngeal neoplasm and tends to affect young adults in Southeast Asia more frequently than other populations.
2. Adenoid cystic carcinoma: This is a rare, slow-growing tumor that usually affects the nasopharynx and salivary glands.
3. Metastatic squamous cell carcinoma: This is a type of cancer that originates in another part of the body (usually the head and neck) and spreads to the nasopharynx.
4. Lymphoma: This is a type of cancer that affects the immune system and can occur in the nasopharynx.
5. Benign tumors: These include benign growths such as papillomas, fibromas, and meningiomas.
Symptoms of nasopharyngeal neoplasms can vary depending on the size and location of the tumor but may include:
* Difficulty swallowing
* Nosebleeds
* Headaches
* Facial pain or numbness
* Trouble breathing through the nose
* Hoarseness or voice changes
* Enlarged lymph nodes in the neck
Diagnosis of nasopharyngeal neoplasms usually involves a combination of imaging tests such as CT or MRI scans, endoscopy (insertion of a flexible tube with a camera into the nose and throat), and biopsy (removal of a small sample of tissue for examination under a microscope).
Treatment of nasopharyngeal neoplasms depends on the type, size, location, and stage of the tumor but may include:
* Surgery to remove the tumor
* Radiation therapy to kill cancer cells
* Chemotherapy to kill cancer cells
* Targeted therapy to attack specific molecules on cancer cells
Prognosis for nasopharyngeal neoplasms varies depending on the type and stage of the tumor but in general, early detection and treatment improve the chances of a successful outcome.
There are several types of thyroid neoplasms, including:
1. Thyroid nodules: These are abnormal growths or lumps that can develop in the thyroid gland. Most thyroid nodules are benign (non-cancerous), but some can be malignant (cancerous).
2. Thyroid cancer: This is a type of cancer that develops in the thyroid gland. There are several types of thyroid cancer, including papillary, follicular, and medullary thyroid cancer.
3. Thyroid adenomas: These are benign tumors that develop in the thyroid gland. They are usually non-cancerous and do not spread to other parts of the body.
4. Thyroid cysts: These are fluid-filled sacs that can develop in the thyroid gland. They are usually benign and do not cause any symptoms.
Thyroid neoplasms can be caused by a variety of factors, including genetic mutations, exposure to radiation, and certain medical conditions, such as thyroiditis (inflammation of the thyroid gland).
Symptoms of thyroid neoplasms can include:
* A lump or swelling in the neck
* Pain in the neck or throat
* Difficulty swallowing or breathing
* Hoarseness or voice changes
* Weight loss or fatigue
Diagnosis of thyroid neoplasms usually involves a combination of physical examination, imaging tests (such as ultrasound or CT scans), and biopsies. Treatment depends on the type and severity of the neoplasm, and can include surgery, radiation therapy, and medications.
This definition of 'Neoplasm Recurrence, Local' is from the Healthcare Professionals edition of the Merriam-Webster Medical Dictionary, copyright © 2007 by Merriam-Webster, Inc.
There are several types of lung neoplasms, including:
1. Adenocarcinoma: This is the most common type of lung cancer, accounting for approximately 40% of all lung cancers. It is a malignant tumor that originates in the glands of the respiratory tract and can be found in any part of the lung.
2. Squamous cell carcinoma: This type of lung cancer accounts for approximately 25% of all lung cancers and is more common in men than women. It is a malignant tumor that originates in the squamous cells lining the airways of the lungs.
3. Small cell lung cancer (SCLC): This is a highly aggressive form of lung cancer that accounts for approximately 15% of all lung cancers. It is often found in the central parts of the lungs and can spread quickly to other parts of the body.
4. Large cell carcinoma: This is a rare type of lung cancer that accounts for only about 5% of all lung cancers. It is a malignant tumor that originates in the large cells of the respiratory tract and can be found in any part of the lung.
5. Bronchioalveolar carcinoma (BAC): This is a rare type of lung cancer that originates in the cells lining the airways and alveoli of the lungs. It is more common in women than men and tends to affect older individuals.
6. Lymphangioleiomyomatosis (LAM): This is a rare, progressive, and often fatal lung disease that primarily affects women of childbearing age. It is characterized by the growth of smooth muscle-like cells in the lungs and can lead to cysts, lung collapse, and respiratory failure.
7. Hamartoma: This is a benign tumor that originates in the tissue of the lungs and is usually found in children. It is characterized by an overgrowth of normal lung tissue and can be treated with surgery.
8. Secondary lung cancer: This type of cancer occurs when cancer cells from another part of the body spread to the lungs through the bloodstream or lymphatic system. It is more common in people who have a history of smoking or exposure to other carcinogens.
9. Metastatic cancer: This type of cancer occurs when cancer cells from another part of the body spread to the lungs through the bloodstream or lymphatic system. It is more common in people who have a history of smoking or exposure to other carcinogens.
10. Mesothelioma: This is a rare and aggressive form of cancer that originates in the lining of the lungs or abdomen. It is caused by asbestos exposure and can be treated with surgery, chemotherapy, and radiation therapy.
Lung diseases can also be classified based on their cause, such as:
1. Infectious diseases: These are caused by bacteria, viruses, or other microorganisms and can include pneumonia, tuberculosis, and bronchitis.
2. Autoimmune diseases: These are caused by an overactive immune system and can include conditions such as sarcoidosis and idiopathic pulmonary fibrosis.
3. Genetic diseases: These are caused by inherited mutations in genes that affect the lungs and can include cystic fibrosis and primary ciliary dyskinesia.
4. Environmental diseases: These are caused by exposure to harmful substances such as tobacco smoke, air pollution, and asbestos.
5. Radiological diseases: These are caused by exposure to ionizing radiation and can include conditions such as radiographic breast cancer and lung cancer.
6. Vascular diseases: These are caused by problems with the blood vessels in the lungs and can include conditions such as pulmonary embolism and pulmonary hypertension.
7. Tumors: These can be benign or malignant and can include conditions such as lung metastases and lung cancer.
8. Trauma: This can include injuries to the chest or lungs caused by accidents or other forms of trauma.
9. Congenital diseases: These are present at birth and can include conditions such as bronchopulmonary foregut malformations and congenital cystic adenomatoid malformation.
Each type of lung disease has its own set of symptoms, diagnosis, and treatment options. It is important to seek medical attention if you experience any persistent or severe respiratory symptoms, as early diagnosis and treatment can improve outcomes and quality of life.
Some common types of breast diseases include:
1. Fibrocystic breast disease: A condition characterized by the formation of small lumps or cysts in the breast tissue, often accompanied by breast pain.
2. Fibroadenoma: A benign tumor that is made up of glandular and fibrous tissue, typically found in young women.
3. Ductal carcinoma in situ (DCIS): A type of cancer that originates in the milk ducts and has not spread to other parts of the breast or body.
4. Invasive ductal carcinoma (IDC): The most common type of breast cancer, which starts in the milk ducts but has invaded the surrounding tissue.
5. Invasive lobular carcinoma (ILC): A type of breast cancer that starts in the milk-producing glands (lobules) and has invaded the surrounding tissue.
6. Breast abscess: A collection of pus in the breast tissue, often caused by an infection.
7. Mastitis: An inflammation of the breast tissue, usually caused by a bacterial infection.
8. Breast cancer recurrence: Cancer that has returned after previous treatment.
Early detection and diagnosis of breast diseases are crucial for effective treatment and improved outcomes. Screening tests such as mammography, ultrasound, and biopsy can help identify breast diseases at an early stage, when they are more treatable. Treatment options for breast diseases depend on the type and severity of the condition, and may include surgery, chemotherapy, radiation therapy, or hormone therapy.
The cancer cells of this type are thought to arise from abnormalities in the cells that line the ducts of the salivary glands. These abnormal cells grow and divide uncontrollably, forming a mass that can obstruct the flow of saliva and cause symptoms such as pain, swelling, and difficulty eating or speaking.
Mucoepidermoid carcinoma is typically diagnosed with a combination of imaging studies, such as CT scans, MRI, and PET scans, and a biopsy, where a sample of tissue is removed from the tumor and examined under a microscope for cancer cells. Treatment typically involves surgery to remove the tumor, followed by radiation therapy and/or chemotherapy to kill any remaining cancer cells.
Prognosis for this type of cancer is generally good if it is diagnosed early and treated promptly, but it can be challenging to treat if it has spread to other parts of the body.
Example Sentences:
The patient was diagnosed with adenosquamous carcinoma of the lung and underwent surgical resection.
The pathology report revealed that the tumor was an adenosquamous carcinoma, which is a rare type of lung cancer.
Note: Adenosquamous carcinoma is a rare subtype of non-small cell lung cancer (NSCLC), accounting for approximately 1-3% of all lung cancers. It has a more aggressive clinical course and poorer prognosis compared to other types of NSCLC.